Cost-effectiveness of Human Papillomavirus Vaccination in the United States

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Chesson, Harrell W. ; Ekwueme, Donatus U. ; Saraiya, Mona ; Markowitz, Lauri E.
• Description:
  We describe a simplified model, based on the current economic and health effects of human papillomavirus (HPV), to estimate the cost-effectiveness of HPV vaccination of 12-year-old girls in the United States. Under base-case parameter values, the estimated cost per quality-adjusted life year gained by vaccination in the context of current cervical cancer screening practices in the United States ranged from $3,906 to $14,723 (2005 US dollars), depending on factors such as whether herd immunity effects were assumed; the types of HPV targeted by the vaccine; and whether the benefits of preventing anal, vaginal, vulvar, and oropharyngeal cancers were included. The results of our simplified model were consistent with published studies based on more complex models when key assumptions were similar. This consistency is reassuring because models of varying complexity will be essential tools for policy makers in the development of optimal HPV vaccination strategies.
• Subjects:
  Adolescent Cervical Intraepithelial Neoplasia Child Cost-Benefit Analysis Disease Progression Female Health Policy Humans Immunization Programs Models, Econometric Papillomaviridae Papillomavirus Infections Papillomavirus Vaccines Quality-Adjusted Life Years Research Uterine Cervical Neoplasms Vaccination

  More +
• Source:
  Emerg Infect Dis. 14(2):244-251.
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Location:
  North America
• Volume:
  14
• Issue:
  2
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:21487ac18e3b5307993b2f51f77cf4500fe73dc1c1667b05fd0114113814cb8e
• Download URL:
  https://stacks.cdc.gov/view/cdc/3177/cdc_3177_DS1.pdf
• File Type:
  [PDF - 365.12 KB ]